title: Aspirin and lipid mediators in the cardiovascular system.
abstract: Aspirin is an unique compound because it bears two active moieties within one and the same molecule: a reactive acetyl group and the salicylate metabolite. Salicylate has some effects similar to aspirin, however only at higher concentrations, usually in the millimolar range, which are not obtained at conventional antiplatelet aspirin doses of 100-300 mg/day. Pharmacological actions of aspirin in the cardiovascular system at these doses are largely if not entirely due to target structure acetylation. Several classes of lipid mediators become affected: Best known is the cyclooxygenase-1 (COX-1) in platelets with subsequent inhibition of thromboxane and, possibly, thrombin formation. By this action, aspirin also inhibits paracrine thromboxane functions on other lipid mediators, such as the platelet storage product sphingosine-1-phosphate (S1P), an inflammatory mediator. Acetylation of COX-2 allows for generation of 15-(R)HETE and subsequent formation of "aspirin-triggered lipoxin" (ATL) by interaction with white cell lipoxygenases. In the cardiovascular system, aspirin also acetylates eNOS with subsequent upregulation of NO formation and enhanced expression of the antioxidans heme-oxygenase-1. This action is possibly also COX-2/ATL mediated. Many more acetylation targets have been identified in live cells by quantitative acid-cleavable activity-based protein profiling and might result in discovery of even more aspirin targets in the near future.
authors.affiliation: Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf and *Institut für Pharmakologie, Ernst-Moritz Arndt Universität, Greifswald, Germany. Electronic address: schroer.frechen@uni-duesseldorf.de.
authors.forename: Karsten
authors.initials: K
authors.lastname: Schrör
authors.affiliation: Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf and *Institut für Pharmakologie, Ernst-Moritz Arndt Universität, Greifswald, Germany.
authors.forename: Bernhard H
authors.initials: BH
authors.lastname: Rauch
mesh_terms: D001241:Aspirin / Q000009:adverse effects / Q000493:pharmacokinetics / Q000494:pharmacology*; D002319:Cardiovascular System / Q000187:drug effects* / Q000378:metabolism*; D006801:Humans; D050356:Lipid Metabolism / Q000187:drug effects*; D058990:Molecular Targeted Therapy
chemical_list: D001241:Aspirin
keywords: Aspirin; Cycloxygenases; Lipoxins; Nitric oxide; Prostaglandins; Sphingosine-1-phosphate; Thromboxane